Explore the words cloud of the RV001 project. It provides you a very rough idea of what is the project "RV001" about.
The following table provides information about the project.
|Coordinator Country||Denmark [DK]|
|Total cost||5˙273˙880 €|
|EC max contribution||2˙499˙900 € (47%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-10-01 to 2022-09-30|
Take a look of project's partnership.
Prostate cancer is the most commonly diagnosed cancer in men, with 1.7M new cases and 0.5M deaths anticipated by 2030 worldwide. Although metastases are responsible in 90% of cancer deaths, in today’s standard treatment there is no active therapy after removal of primary tumor to prevent metastasis formation. 40% of patients experience relapse of cancer in the first 2 years after surgery. The existing treatments focusing on later stages, do not prevent the initial spread of metastatic cells and cause numerous undesirable side effects. Late stage immunotherapies against metastatic cancer also present major drawbacks, including high costs and adverse events. So, there is a critical unmet need for a therapy that can effectively prevent metastasis formation in early stage prostate cancer. RhoVac aims to address this need by developing the first therapeutic vaccine against early stage metastases in prostate cancer – RV001 – which could revolutionize the treatment of metastatic cancer. Through the activation of the patient’s own immune system, RhoVac projects that RV001 will induce the specific elimination of metastatic cancer cells with unprecedented levels of safety, tolerability and biological activity, proven with the successful conclusion of a Phase I/II clinical trial in 2018. RhoVac aims to develop the RV001 vaccine up to completion of a Phase IIb clinical trial (key objective of the present project), following which the company plans to out-license the vaccine to a large Pharma, with conservatively predicted revenues of ca. €1B, within 5 years of vaccine launch. Due to its mechanism, RV001 could potentially be used against all metastatic cancer types. RhoVac will seek to validate this exploratively in parallel with the prostate cancer project. In short, our aim to introduce “metastatic prevention” as new paradigm in cancer treatment, rather than relying on the frequently ineffective treatment of metastases that have already formed.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RV001" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RV001" are provided by the European Opendata Portal: CORDIS opendata.
First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatusRead More
NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEMRead More
FAST-RESPONSIVE and LONG-LASTING TRANSPARENT PHOTOCHROMIC FILMSRead More